Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2017 | Venetoclax: a lifesaving drug for CLL patients

Christopher Fox • 29 Mar 2017
BSH 2017
Chronic Lymphocytic Leukemia Ibrutinib Venetoclax

Christopher Fox, MBChB, MRCP, FRCPath, from Nottingham University Hospital, Nottingham, UK discusses the success of venetoclax in treating patients with chronic lymphocytic leukemia (CLL) at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Up until recently, patients who failed or were intolerant to BCR inhibitor therapy, such as ibrutinib, had a dismal prognosis. However, results from the CLL forum data study have shown improved survival outcomes for patients on venetoclax who had previously failed other first-line therapy. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.

More from Christopher Fox

2:09
Primary CNS lymphoma: can we use MATRix immunochemo in the real world?
Christopher Fox • 16 Apr 2018
1:45
An unmet need in CLL: patients failing ibrutinib and idelalisib
Christopher Fox • 14 Apr 2018
1:26
The role of TP53 in CLL
Christopher Fox • 14 Apr 2018
1:10
CheckMate study and the role of nivolumab in Hodgkin lymphoma
Christopher Fox • 27 Mar 2017

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals